

11

Express Mail Label No. EL302645404US



PATENT
Attorney Docket No. LEX-003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Gillies *et al.*

SERIAL NUMBER: 09/256,156

GROUP NUMBER: 1644

FILING DATE: February 24, 1999

EXAMINER: J. Murphy

TITLE: ENHANCING THE CIRCULATING HALF LIFE OF
ANTIBODY-BASED FUSION PROTEINS

RESPONSE TO RESTRICTION REQUIREMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:


In the Office Action mailed from the U.S. Patent Office on April 10, 2000 for the above-identified patent application, the Examiner requires Applicants to restrict prosecution to one of two Groups of claims, each Group being said to recite a distinct invention. Specifically, Group I comprises claims 1-13 and 25, and Group II comprises claims 14-24 and 26.

Applicants provisionally elect, with traverse, to prosecute the invention of Group I (claims 1-13 and 25) directed to "an antibody-based fusion protein with an enhanced circulating half-life, classified in class 530, subclass 387.3."

Response to Restriction Requirement
U.S. Serial No. 09/256,156
Page 2

If the Examiner believes a conversation with Applicants' agent would be helpful in expediting prosecution of this application, the Examiner is invited to call the undersigned agent at (617) 248-7240.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Pat R.H. Waller". The signature is fluid and cursive, with the first name "Pat" being more prominent.

Patrick R.H. Waller
Registration No. 41,418

Dated: June 12, 2000

TESTA, HURWITZ & THIBEAULT, LLP
High Street Tower
125 High Street
Boston, MA 02110

Tel: (617) 248-7240
Fax: (617) 248-7100

1014561